DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Information source: NuSirt Biopharma
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 2 Diabetes Mellitus

Intervention: Low Metformin (Drug); Mid Metformin (Drug); High Metformin (Drug); Metformin (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: NuSirt Biopharma

Official(s) and/or principal investigator(s):
Orville Kolterman, MD, Study Chair, Affiliation: Pharmapace


Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i. e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.

Clinical Details

Official title: An Extension of Protocol NS-0100-01 to Evaluate the Safety and Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Mono-therapy on Glycemic Control in Subjects With Type 2 Diabetes

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change in HbA1c levels in patient receiving the various doses of Leucine and Metformin combinations

Secondary outcome:

Change in fasting plasma glucose

Change in HOMA-IR

Change in baseline corrected plasma glucose

Change in baseline corrected plasma insulin

Change in fasting plasma lipids

Change in 7 point glucose profiles

Detailed description: This is a randomized, 8-week, extension of Study NS-0100-01, to evaluate the effect of various fixed-dose (FDC) combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control. Subjects meeting all inclusion criteria and no exclusion criteria for the extension study, including completion of the 4-week treatment period of Study NS-0100-01 [Day 28/Visit 7]), will be eligible to enroll into the extension. During participation in the extension, subjects will continue to receive their assigned treatment based upon the randomization that occurred on Day 1 (Visit 4) of Study NS-0100-0. The study will include a total of 3 visits: Visit 1E (Day 28/Visit 7 of Study NS-0100-01), Visit 2E (Day 56/Week 8), and Visit 3E (Day 84/Week 12). Key assessments at Visit 2E and Visit 3E include HbA1c, fasting plasma glucose, and plasma insulin. In addition, 3-hour standardized meal tests will be performed on Day 28 (as part of the Study Termination [Visit 7] procedures of Study NS-0100-01 prior to enrolling into the extension) and at Study Termination for the extension (Visit 3E [Day 84/Week 12]).


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Has completed Study NS-0100-01, including all procedures required at Study Termination (Day 28/Visit 7) without major protocol deviations 2. Is male, or female and, if female, meets all of the following criteria:

- Not breastfeeding

- Post-menopausal or negative pregnancy test result (human chorionic gonadotropin,

beta subunit [β-hCG]) at Screening (Visit 1) (not required for hysterectomized females)

- If of childbearing potential (including perimenopausal women who have had a

menstrual period within one year) and sexually active, must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i. e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectables, oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or a vasectomized partner) during the entire duration of the study. 3. Is able to read, understand, and sign the informed consent forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements. Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from the study. 1. Is undesirable as a study participant as judged by the investigator (e. g., exhibited poor compliance during Study NS-0100-01) 2. Is expected to require treatment, or if currently on a stable dose, changes to their regimen of the following medications:

- Lipid-lowering agents

- Anti-hypertensive medications

- Thyroid replacement therapy

- Non-steroidal anti-inflammatory agents

3. Is expected to require or undergo treatment with any of the following medications:

- Antidiabetes medications (with the exception of study medication [i. e.,


- Oral or parenteral steroids.

Locations and Contacts

Catalina Research Institute, Chino, California 91710, United States

Palm Beach Research, Palm Beach, Florida 33409, United States

Meridien Research, Tampa, Florida 33606, United States

River Birch Research Alliance, Blue Ridge, Georgia 3051313, United States

Meridian Research, Savannah, Georgia 31406, United States

Streling Research Group, Cincinnati, Ohio 45219, United States

Medical Research South, Charleston, South Carolina 29407, United States

Meharry Medical College, Nashville, Tennessee 37208, United States

Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism, Nashville, Tennessee 37232, United States

Additional Information

Starting date: October 2014
Last updated: August 20, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017